Skip to main content
Clinical Trials/ACTRN12618000706279
ACTRN12618000706279Completed未知

The effect of high-polyphenol extra virgin olive oil on markers of cardiovascular disease risk in healthy Australian adults.

a Trobe University0 sites50 target enrollmentStarted: April 30, 2018Last updated:
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Sponsor
Enrollment
50

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Randomised controlled trial
Primary Purpose
Prevention
Masking
Blinded (masking used)

Eligibility Criteria

Ages
18 Years to 75 Years (—)
Sex
All

Inclusion Criteria

  • Aged 18-75 years

Exclusion Criteria

  • The exclusion criteria of Post and peri-menopausal women has been removed. More specifically the updated list of the key exclusion criteria is as follows:
  • Non-English-speaking persons
  • Pregnant or lactating women
  • History of adverse reactions to olive oil (
  • Currently prescribed warfarin, anti-coagulant therapy, statin medications, all oral hypoglycaemic agents, insulin, cyclosporine, tacrolimus, immunosuppressant agents, antihypertensive agents, and nonsteroidal anti-inflammatory drugs (hypothesised interactions), hormone replacement therapy
  • A habitual diet with greater than or equal to 1 tablespoon of olive oil per day;
  • Current smoker;
  • Use of antioxidant supplements or medications with antioxidant properties,
  • Diagnosed with any of the following conditions: hyperlipidaemia; diabetes mellitus; hypertension; inflammatory conditions (e.g. rheumatoid arthritis), intestinal disease (e.g. inflammatory bowel disease); irritable bowel syndrome, food intolerances, blood coagulation disorders, or any other physiological condition or disease that could impair adherence.
  • -Unstable body weight within =/>5kg weight fluctuations in the prior 3 months
  • -Special diet for medical reasons (i.e gluten free for coeliac disease)
  • Exclusion criteria for cognition component only.
  • -Currently prescribed antidepressant medication

Investigators

Sponsor
a Trobe University

Similar Trials